von Tobias Borgers | Aug 26, 2019 | Allgemein
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corporation (NASDAQ: CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (NASDAQ: AMGN) under...
von Tobias Borgers | Jul 29, 2019 | Allgemein
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb’s pending acquisition of Celgene Corporation (NASDAQ:CELG). “Clearance from the...
von Tobias Borgers | Jul 29, 2019 | Allgemein
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo ® (nivolumab) plus low-dose Yervoy ® (ipilimumab) met the co-primary endpoint of overall survival...
von Tobias Borgers | Jul 23, 2019 | Allgemein
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation...
von Tobias Borgers | Jul 18, 2019 | Allgemein
WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan–(BUSINESS WIRE)–Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to...
